Carlos A Morillo1, Jose Antonio Marin-Neto, Alvaro Avezum, Sergio Sosa-Estani, Anis Rassi, Fernando Rosas, Erick Villena, Roberto Quiroz, Rina Bonilla, Constança Britto, Felipe Guhl, Elsa Velazquez, Laura Bonilla, Brandi Meeks, Purnima Rao-Melacini, Janice Pogue, Antonio Mattos, Janis Lazdins, Anis Rassi, Stuart J Connolly, Salim Yusuf. 1. From the Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada (C.A.M., L.B., B.M., P.R.-M., J.P., S.J.C., S.Y.); Cardiology Division, Internal Medicine Department, Medical School of Riberao Preto (J.A.M.-N.), Instituto Dante Pazzanese de Cardiologia, São Paulo (A.A., A.M.), Hospital do Coração Anis Rassi, Goiãnia (A. Rassi Jr., A. Rassi), and Fiocruz, Instituto Oswaldo Cruz, Laboratório de Biologia Molecular e Doenças Endêmicas, Rio de Janeiro (C.B.) - all in Brazil; Instituto Nacional de Parasitología Dr. Mario Fatala Chaben-Administración Nacional de Laboratorios e Institutos de Salud, Buenos Aires (S.S.-E., E. Velazquez); Fundación Clínica Abood Shaio (F.R.) and CIMPAT-Facultad de Ciencias, Universidad de los Andes (F.G.), Bogota, and Fundación Cardiovascular de Colombia, Bucaramanga (R.Q.) - all in Colombia; Hospital Eduardo Eguia, Programa Chagas, Tupiza, Bolivia (E. Villena); Hospital Nacional Rosales, San Salvador, El Salvador (R.B.); and Independent Advisor, Neglected Tropical Diseases, Geneva (J.L.).
Abstract
BACKGROUND: The role of trypanocidal therapy in patients with established Chagas' cardiomyopathy is unproven. METHODS: We conducted a prospective, multicenter, randomized study involving 2854 patients with Chagas' cardiomyopathy who receivedbenznidazole or placebofor up to 80 days and were followed for a mean of 5.4 years. The primary outcome in the time-to-event analysis was the first event of any of the components of the composite outcome of death, resuscitated cardiac arrest, sustained ventricular tachycardia, insertion of a pacemaker or implantable cardioverter-defibrillator, cardiac transplantation, new heart failure, stroke, or other thromboembolic event. RESULTS: The primary outcome occurred in 394 patients (27.5%) in the benznidazole group and in 414 (29.1%) in the placebo group (hazard ratio, 0.93; 95% confidence interval [CI], 0.81 to 1.07; P=0.31). At baseline, a polymerase-chain-reaction (PCR) assay was performed on blood samples obtained from 1896 patients; 60.5% had positive results for Trypanosoma cruzi on PCR. The rates of conversion to negative PCR results (PCR conversion) were 66.2% in the benznidazole group and 33.5% in the placebo group at the end of treatment, 55.4% and 35.3%, respectively, at 2 years, and 46.7% and 33.1%, respectively, at 5 years or more (P<0.001 for all comparisons). The effect of treatment on PCR conversion varied according to geographic region: in Brazil, the odds ratio for PCR conversion was 3.03 (95% CI, 2.12 to 4.34) at 2 years and 1.87 (95% CI, 1.33 to 2.63) at 5 or more years; in Colombia and El Salvador, the odds ratio was 1.33 (95% CI, 0.90 to 1.98) at 2 years and 0.96 (95% CI, 0.63 to 1.45) at 5 or more years; and in Argentina and Bolivia, the odds ratio was 2.63 (95% CI, 1.89 to 3.66) at 2 years and 2.79 (95% CI, 1.99 to 3.92) at 5 or more years (P<0.001 for interaction). However, the rates of PCR conversion did not correspond to effects on clinical outcome (P=0.16 for interaction). CONCLUSIONS:Trypanocidal therapy with benznidazole in patients with established Chagas' cardiomyopathy significantly reduced serum parasite detection but did not significantly reduce cardiac clinical deterioration through 5 years of follow-up. (Funded by the Population Health Research Institute and others; ClinicalTrials.gov number, NCT00123916; Current Controlled Trials number, ISRCTN13967269.).
RCT Entities:
BACKGROUND: The role of trypanocidal therapy in patients with established Chagas' cardiomyopathy is unproven. METHODS: We conducted a prospective, multicenter, randomized study involving 2854 patients with Chagas' cardiomyopathy who received benznidazole or placebo for up to 80 days and were followed for a mean of 5.4 years. The primary outcome in the time-to-event analysis was the first event of any of the components of the composite outcome of death, resuscitated cardiac arrest, sustained ventricular tachycardia, insertion of a pacemaker or implantable cardioverter-defibrillator, cardiac transplantation, new heart failure, stroke, or other thromboembolic event. RESULTS: The primary outcome occurred in 394 patients (27.5%) in the benznidazole group and in 414 (29.1%) in the placebo group (hazard ratio, 0.93; 95% confidence interval [CI], 0.81 to 1.07; P=0.31). At baseline, a polymerase-chain-reaction (PCR) assay was performed on blood samples obtained from 1896 patients; 60.5% had positive results for Trypanosoma cruzi on PCR. The rates of conversion to negative PCR results (PCR conversion) were 66.2% in the benznidazole group and 33.5% in the placebo group at the end of treatment, 55.4% and 35.3%, respectively, at 2 years, and 46.7% and 33.1%, respectively, at 5 years or more (P<0.001 for all comparisons). The effect of treatment on PCR conversion varied according to geographic region: in Brazil, the odds ratio for PCR conversion was 3.03 (95% CI, 2.12 to 4.34) at 2 years and 1.87 (95% CI, 1.33 to 2.63) at 5 or more years; in Colombia and El Salvador, the odds ratio was 1.33 (95% CI, 0.90 to 1.98) at 2 years and 0.96 (95% CI, 0.63 to 1.45) at 5 or more years; and in Argentina and Bolivia, the odds ratio was 2.63 (95% CI, 1.89 to 3.66) at 2 years and 2.79 (95% CI, 1.99 to 3.92) at 5 or more years (P<0.001 for interaction). However, the rates of PCR conversion did not correspond to effects on clinical outcome (P=0.16 for interaction). CONCLUSIONS: Trypanocidal therapy with benznidazole in patients with established Chagas' cardiomyopathy significantly reduced serum parasite detection but did not significantly reduce cardiac clinical deterioration through 5 years of follow-up. (Funded by the Population Health Research Institute and others; ClinicalTrials.gov number, NCT00123916; Current Controlled Trials number, ISRCTN13967269.).
Authors: Kathryn Jones; Leroy Versteeg; Ashish Damania; Brian Keegan; April Kendricks; Jeroen Pollet; Julio Vladimir Cruz-Chan; Fabian Gusovsky; Peter J Hotez; Maria Elena Bottazzi Journal: Infect Immun Date: 2018-03-22 Impact factor: 3.441
Authors: Irene Losada Galván; Olaya Madrid Pascual; Juan María Herrero-Martínez; Ana Pérez-Ayala; Manuel Lizasoain Hernández Journal: Am J Trop Med Hyg Date: 2019-06 Impact factor: 2.345
Authors: Kyndall C Dye-Braumuller; Rodion Gorchakov; Sarah M Gunter; David H Nielsen; Walter D Roachell; Anna Wheless; Mustapha Debboun; Kristy O Murray; Melissa S Nolan Journal: Vector Borne Zoonotic Dis Date: 2018-12-20 Impact factor: 2.133
Authors: Sabine Ottilie; Gregory M Goldgof; Claudia Magalhaes Calvet; Gareth K Jennings; Greg LaMonte; Jake Schenken; Edgar Vigil; Prianka Kumar; Laura-Isobel McCall; Eduardo Soares Constantino Lopes; Felicia Gunawan; Jennifer Yang; Yo Suzuki; Jair L Siqueira-Neto; James H McKerrow; Rommie E Amaro; Larissa M Podust; Jacob D Durrant; Elizabeth A Winzeler Journal: ACS Chem Biol Date: 2016-12-23 Impact factor: 5.100
Authors: Sandy Park; Daniel R Sanchez; Mahmoud I Traina; Jason S Bradfield; Salvador Hernandez; Alvaro Joaquin Altamirano Ufion; Jalal Dufani; Patrick Bergin; Robin Y Wachsner; Sheba K Meymandi Journal: Am J Trop Med Hyg Date: 2017-05 Impact factor: 2.345
Authors: Christopher A Seid; Kathryn M Jones; Jeroen Pollet; Brian Keegan; Elissa Hudspeth; Molly Hammond; Junfei Wei; C Patrick McAtee; Leroy Versteeg; Amanda Gutierrez; Zhuyun Liu; Bin Zhan; Jonathan L Respress; Ulrich Strych; Maria Elena Bottazzi; Peter J Hotez Journal: Hum Vaccin Immunother Date: 2016-10-13 Impact factor: 3.452
Authors: Kevin M Bonney; Daniel J Luthringer; Stacey A Kim; Nisha J Garg; David M Engman Journal: Annu Rev Pathol Date: 2018-10-24 Impact factor: 23.472
Authors: Andrea C Mesías; Natalia Sasoni; Diego G Arias; Cecilia Pérez Brandán; Oliver C F Orban; Conrad Kunick; Carlos Robello; Marcelo A Comini; Nisha J Garg; M Paola Zago Journal: Free Radic Biol Med Date: 2018-10-23 Impact factor: 7.376